Provided by
| Consensus (mean) in EUR million | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 E |
|---|---|---|---|---|---|
| Orders received | 1,520 | 1,083 | 1,281 | 1,092 | 1,282 |
| - Biomaterial Solutions and Services | 1,144.0 | 738.0 | 908.0 | 693.0 | 897.1 |
| - Process Performance Solutions | 376.0 | 345.0 | 372.0 | 400.0 | 385.0 |
| Net sales | 1,241 | 1,295 | 1,477 | 1,244 | 1,242 |
| - Biomaterial Solutions and Services | 869.0 | 934.0 | 1,067.0 | 904.0 | 861.1 |
| - Process Performance Solutions | 372.0 | 361.0 | 410.0 | 341.0 | 377.7 |
| Comparable EBITA | 143 | 159 | 196 | 114 | 140 |
| - Biomaterial Solutions and Services | 87.0 | 89.0 | 123.0 | 64.0 | 80.8 |
| - Process Performance Solutions | 66.0 | 79.0 | 90.0 | 63.0 | 69.5 |
| Comparable EBITA Margin (%) | 11.5% | 12.3% | 13.3% | 9.2% | 11.3% |
| - Biomaterial Solns. and Servs. | 10.0% | 9.5% | 11.6% | 7.1% | 9.4% |
| - Process Perf. Solns. | 17.8% | 21.9% | 21.9% | 18.5% | 18.4% |
| Adjusted EPS | 0.23 | 0.54 | 0.64 | 0.26 | 0.45 |